ATE503492T1 - Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 - Google Patents

Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Info

Publication number
ATE503492T1
ATE503492T1 AT03789346T AT03789346T ATE503492T1 AT E503492 T1 ATE503492 T1 AT E503492T1 AT 03789346 T AT03789346 T AT 03789346T AT 03789346 T AT03789346 T AT 03789346T AT E503492 T1 ATE503492 T1 AT E503492T1
Authority
AT
Austria
Prior art keywords
hpv16
vaccines against
hpv type
oncogenic hpv
hpv18 vlps
Prior art date
Application number
AT03789346T
Other languages
German (de)
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef Slaoui
M A C Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE503492T1 publication Critical patent/ATE503492T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03789346T 2002-12-20 2003-12-18 Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 ATE503492T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20
PCT/EP2003/014562 WO2004056389A1 (en) 2002-12-20 2003-12-18 Hpv-16 and -18 l1 vlp vaccine

Publications (1)

Publication Number Publication Date
ATE503492T1 true ATE503492T1 (de) 2011-04-15

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03789346T ATE503492T1 (de) 2002-12-20 2003-12-18 Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Country Status (28)

Country Link
US (2) US20060251676A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1572233B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5475939B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (3) KR101361769B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2005003347A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR042530A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE503492T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003293942B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (3) BE2015C068I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR0317544A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2510457C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1111552T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE60336581D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1572233T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA200701633A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP055869A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL169085A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2811B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA27581A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05006764A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY144492A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20052846L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ540811A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA13147A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL215257B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1572233E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI349557B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004056389A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
CA2566620C (en) * 2004-06-16 2014-03-11 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type slected from hpv 31, 45 or 52
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AR053715A1 (es) * 2005-04-26 2007-05-16 Glaxosmithkline Biolog Sa Vacuna multivalente de vph
AR054259A1 (es) * 2005-04-26 2007-06-13 Glaxosmithkline Biolog Sa Vacuna contra virus de papiloma humano (hpv)
WO2008134935A1 (en) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated human papillomavirus type 18 l1 proteins
DK2154147T3 (en) * 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
CA2754533C (en) * 2009-03-05 2019-07-09 Jenny Colleen Mccloskey Treatment of infection
EP2444103B1 (en) * 2009-06-19 2017-12-20 Eyegene Inc. Vaccine for cervical cancer
WO2015114506A2 (en) 2014-01-31 2015-08-06 Marini Bruna Biosensor for the determination of infections and associated pathologies
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
US10238729B2 (en) 2014-10-24 2019-03-26 Hpvvax, Llc Cancer and skin lesion treatment
CN107614009A (zh) * 2015-06-02 2018-01-19 泰尔茂株式会社 含有铝的佐剂组合物及包含其的疫苗组合物
AU2019231652B2 (en) 2018-03-06 2025-05-22 Precigen, Inc. Hepatitis B vaccines and uses of the same
KR20200130339A (ko) 2018-03-06 2020-11-18 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도
CN110551182A (zh) * 2018-06-04 2019-12-10 厦门大学 一种人乳头瘤病毒18型l1蛋白的突变体
CA3121247A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
EP1700911B1 (en) 1997-09-05 2016-04-06 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
JP4841726B2 (ja) * 1999-02-05 2011-12-21 メルク・シャープ・エンド・ドーム・コーポレイション ヒトパピローマウイルスワクチン製剤
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
US20020110566A1 (en) * 2000-06-26 2002-08-15 Neefe John R. Human papilloma virus treatment

Also Published As

Publication number Publication date
JP2006512413A (ja) 2006-04-13
KR20050086924A (ko) 2005-08-30
PL215257B1 (pl) 2013-11-29
EP1572233B1 (en) 2011-03-30
US20050287161A1 (en) 2005-12-29
BR0317544A (pt) 2005-11-22
MY144492A (en) 2011-09-30
DE60336581D1 (de) 2011-05-12
BE2015C067I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2024-08-08
AR042530A1 (es) 2005-06-22
IS7885A (is) 2005-06-09
IL169085A0 (en) 2007-07-04
JP5475939B2 (ja) 2014-04-16
CA2510457C (en) 2011-12-06
CA2510457A1 (en) 2004-07-08
MA27581A1 (fr) 2005-10-03
OA13147A (en) 2006-12-13
AU2003293942A1 (en) 2004-07-14
NZ540811A (en) 2007-03-30
KR101361769B1 (ko) 2014-02-10
BE2015C068I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2024-08-08
AU2003293942B2 (en) 2009-12-10
US20060251676A1 (en) 2006-11-09
TWI349557B (en) 2011-10-01
HK1085378A1 (en) 2006-08-25
WO2004056389A1 (en) 2004-07-08
EA009179B1 (ru) 2007-12-28
EP1572233A1 (en) 2005-09-14
IS2811B (is) 2012-11-15
NO20052846L (no) 2005-07-13
EA200701633A1 (ru) 2007-12-28
PT1572233E (pt) 2011-06-07
AP2005003347A0 (en) 2005-06-30
ECSP055869A (es) 2005-09-20
KR20120123616A (ko) 2012-11-08
EA200500834A1 (ru) 2006-02-24
DK1572233T3 (da) 2011-06-27
MXPA05006764A (es) 2005-09-08
PL377710A1 (pl) 2006-02-06
TW200423957A (en) 2004-11-16
IL169085A (en) 2014-04-30
KR20120118087A (ko) 2012-10-25
CY1111552T1 (el) 2015-08-05
BE2015C069I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2024-08-08

Similar Documents

Publication Publication Date Title
ATE503492T1 (de) Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
AP1872A (en) Virus-like particles of human papillomavirus.
NO2012016I2 (no) Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler
EP1660678A4 (en) MUTANT ADENO-ASSOCIATED VIRUS VIRUSES AND METHOD OF USE THEREOF
LTPA2015049I1 (lt) Žpv 45 l1 optimizuota ekspresija mielėse
DE60236767D1 (de) Medizinische Verwendung eines TetrahydrotriazoloÄ4,3-aÜpyrazins
DE60027440D1 (de) Impfstoff gegen hbv und hpv
DE602004032140D1 (de) Behandlungsvorrichtung mit verwendung von ausgangsstoffgas und reaktivem gas
DE69631246D1 (de) Rekombinante pockenviren des waschbaers sowie ihre verwendung als ein effektiver impfstoff gegen eine infektion mit immunschwaecheviren der katze
DE60230869D1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60312838D1 (de) 1,2,3,4,7,8-HEXAHYDRO-6H-c1,4ÜDIAZEPINOc6,7,1-1JÜCHINOLINDERIVATIVE ALS ANTIPSYCHOTIKA UND MITTEL GEGEN OBESITAS
HUS1500061I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
DE50210920D1 (de) Verwendung von Aluminiumchlorohydrat in Deodoranten und Antiperspiranten
DE60302848D1 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
PL1758609T3 (pl) Szczepionka przeciw HPV16 i HPV18 oraz co najmniej jednemu HPV innego typu wybranemu spośród HPV 31, 45 lub 52
EP1532254A4 (en) VIRUS-FREE HELPER HERPESVIRUS AMPLICON PARTICLES AND ITS USES
DE602005018236D1 (de) Verwendung von aromasubstanzmischungen als mittel gegen schlechten atem
EP1322761A4 (en) HUMANIZED ANTIBODY AGAINST THE HEPATITE B VIRUS SURFACE ANTIGEN AND METHOD OF PREPARING THE SAME
DE60237181D1 (de) Kosmetische Zusammensetzung und Methode um farbentwickelnde Zubereitungen in Kosmetika zu benutzen
ATE456568T1 (de) Kondensierte heterocyclische isoxazolinderivate und deren verwendung als antidepressiva
CY2015048I1 (el) Εμβολιο εναντι hpv16 και hpv18 και τουλαχιστον ενος αλλου τυπου hpv ο οποιος επιλεγεται απο hpv 31,45 ή 52
WO2002055542A3 (de) Hpv-spezifische peptide, die die bindung von hpv an die wirtszelle blockieren
HK1103634A (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
Chi Prospectives of research institute of healthcare policy, Korean Medical Association

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1572233

Country of ref document: EP